...A. We're going to focus on two solid tumor programs, our TGF beta receptor 2xPD-1 bi-specific and our KRAS G12D inhibitor. B. For our TGF beta receptor 2xPD-1, we're going to focus on MSS colorectal cancer. C. As you know, this is -- 80%, 85%, maybe sometimes 90% of the patients with colorectal cancer continues to be an acute medical need because it doesn't respond to PD-1 inhibitors through checkpoint inhibitors. D. The response rate was 0 in 3 of the trials and 2% in another one of the studies. E. The second tumor of interest for today is pancreatic adenocarcinoma, PDAC, for our G12D program. F. Two bispecific will be FOLFOX plus bevacizumab. G. We'll refer to this as INCA890. H. We have TGF beta R2....
